¼¼°èÀÇ Ç÷¾× °Ë»ç ½ÃÀå
Blood Screening
»óǰÄÚµå : 1563846
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 158 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,301,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,905,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Ç÷¾× °Ë»ç ¼¼°è ½ÃÀå, 2030³â±îÁö 38¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»ó

2023³â 26¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°è Ç÷¾× °Ë»ç ½ÃÀåÀº 2023-2030³â µ¿¾È ¿¬Æò±Õ 5.6%ÀÇ ¼ºÀå·üÀ» ±â·ÏÇÏ¿© 2030³â¿¡´Â 38¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÇÙ»ê °Ë»ç(NAT)´Â CAGR 5.3%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö 17¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. È¿¼Ò °áÇÕ ¸é¿ª ÈíÂø ºÐ¼®¹ý(ELISA) ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È 6.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 6¾ï 9,770¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.1%·Î ¼ºÀå Àü¸Á

¹Ì±¹ Ç÷¾× °Ë»ç ½ÃÀåÀº 2023³â 6¾ï 9,770¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2023-2030³âÀÇ ºÐ¼® ±â°£ µ¿¾È 9.1%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³»°í, 2030³â¿¡´Â 8¾ï 3,140¸¸ ´Þ·¯ ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ °¢°¢ 1.9%¿Í 6.0%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è Ç÷¾× °Ë»ç ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

Ç÷¾× °Ë»ç°¡ ¾ÈÀüÇÑ °Ç°­ °ü¸®¿¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Ç÷¾× °Ë»ç´Â ¼öÇ÷, Àå±â À̽Ä, Áø´Ü ¸ñÀûÀ¸·Î »ç¿ëµÇ±â Àü¿¡ Ç÷¾× »ùÇÿ¡¼­ °¨¿° ÀÎÀÚ, À¯Àü Áúȯ ¹× ±âŸ °Ç°­ »óŸ¦ °¨ÁöÇϵµ·Ï ¼³°èµÈ °Ç°­ °ü¸®ÀÇ Áß¿äÇÑ °úÁ¤ÀÔ´Ï´Ù. ÀÌ ¼±º° °úÁ¤Àº Ç÷¾× ¹× Ç÷¾× Á¦Á¦ÀÇ ¾ÈÀü¼ºÀ» º¸ÀåÇϰí HIV, °£¿°, ¸Åµ¶°ú °°Àº °¨¿°º´À» ¿¹¹æÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. Ç÷¾× °Ë»ç´Â ¶ÇÇÑ ¾Ï, À¯Àü¼º À¯Àü Áúȯ µîÀÇ Á¶±â ¹ß°ß¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ¿© Àû½Ã¿¡ °³ÀÔÇϰí Ä¡·áÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. Ç÷¾× ¼±º° °Ë»çÀÇ Á¤È®¼º°ú ½Å·Ú¼ºÀº ȯÀÚÀÇ ¾ÈÀü°ú °øÁß º¸°Ç¿¡ Á÷Á¢ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡±â ¶§¹®¿¡ °¡Àå Áß¿äÇÕ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¾ÈÀüÇÑ Ç÷¾×Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó Ç÷¾× °Ë»ç´Â ȯÀÚ¸¦ º¸È£Çϰí Ä¡·áÀÇ È¿°ú¸¦ º¸ÀåÇÏ´Â Çö´ë ÀÇ·áÀÇ Çʼö ¿ä¼Ò·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº Ç÷¾× °Ë»ç °úÁ¤À» ¾î¶»°Ô º¯È­½ÃÄ×À»±î?

±â¼úÀÇ ¹ßÀüÀ¸·Î Ç÷¾× °Ë»ç ºÐ¾ß´Â ´õ ºü¸£°í, ´õ Á¤È®Çϰí, ´õ Á¾ÇÕÀûÀÎ °Ë»ç ¹æ¹ýÀ¸·Î º¯¸ðÇϰí ÀÖ½À´Ï´Ù. ±âÁ¸ Ç÷¾× °Ë»ç´Â ¼öÀÛ¾÷°ú ±âº»ÀûÀÎ Ç÷ûÇÐÀû °Ë»ç¿¡ ÀÇÁ¸ÇØ ¿ÔÀ¸¸ç, ÀÌ´Â È¿°úÀûÀÌÁö¸¸ ¹üÀ§°¡ Á¦ÇÑÀûÀÌ°í °á°ú°¡ ³ª¿À±â±îÁö ¸çÄ¥ÀÌ °É¸®±âµµ Çß½À´Ï´Ù. ÀÚµ¿ °Ë»ç ½Ã½ºÅÛ°ú ºÐÀÚÁø´ÜÇÐÀÇ µµÀÔÀ¸·Î Ç÷¾× °Ë»çÀÇ ¼Óµµ¿Í Á¤È®µµ°¡ ºñ¾àÀûÀ¸·Î Çâ»óµÇ¾ú½À´Ï´Ù. ÇÙ»ê °Ë»ç(NAT)¿Í °°Àº ±â¼úÀ» ÅëÇØ ¹ÙÀÌ·¯½º ¹× ¼¼±Õ º´¿øÃ¼¸¦ Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ°Ô µÇ¾î ¼öÇ÷·Î ÀÎÇÑ °¨¿° À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ´ë·® Ç÷¾× »ùÇÃÀ» º¸´Ù È¿À²ÀûÀ¸·Î ó¸®ÇÒ ¼ö ÀÖ´Â °í󸮷® ½ºÅ©¸®´× ½Ã½ºÅÛÀÇ °³¹ßÀº Çö´ë ÀÇ·á ½Ã¼³ÀÇ ¿ä±¸¿¡ ºÎÀÀÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. °á°úÀûÀ¸·Î Ç÷¾× °Ë»ç ±â¼úÀÇ ¹ßÀüÀº Ç÷¾× Á¦Á¦ÀÇ ¾ÈÀü¼ºÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó °ËÃâ °¡´ÉÇÑ Áúº´ÀÇ ¹üÀ§¸¦ È®´ëÇÏ¿© ¿¹¹æ ÀÇ·áÀÇ ÇÙ½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù.

Ç÷¾× °Ë»ç ±â¼úÀÇ »õ·Î¿î Æ®·»µå¿Í Çõ½ÅÀ̶õ?

Ç÷¾× °Ë»ç´Â º¸´Ù Á¾ÇÕÀûÀÌ°í ½Å¼ÓÇÏ¸ç ºñ¿ë È¿À²ÀûÀÎ Áø´Ü ¼Ö·ç¼ÇÀÇ Çʿ伺À¸·Î ÀÎÇØ ÇöÀç Å« Çõ½ÅÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. °¡Àå ÁÖ¸ñÇÒ ¸¸ÇÑ Æ®·»µå Áß Çϳª´Â Ç÷¾× °Ë»ç¿¡ Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®±â(NGS)ÀÇ »ç¿ëÀÌ È®´ëµÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. À̸¦ ÅëÇØ À¯Àü ¹°Áú¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®ÀÌ °¡´ÉÇØÁ® ÇÑ ¹øÀÇ Ç÷¾× »ùÇÿ¡¼­ ´Ù¾çÇÑ º´¿øÃ¼¿Í À¯Àü ÁúȯÀ» ½Äº°ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶Ç ´Ù¸¥ »õ·Î¿î Æ®·»µå´Â ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×À» Ç÷¾× °Ë»ç ÇÁ·Î¼¼½º¿¡ ÅëÇÕÇÏ¿© ±âÁ¸ ¹æ¹ýÀ¸·Î´Â ³õÄ¥ ¼ö ÀÖ´Â ÆÐÅϰú ÀÌ»óÀ» ½Äº°ÇÏ¿© Áø´ÜÀÇ Á¤È®µµ¸¦ ³ôÀÌ´Â °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ÇöÀåÁø´Ü(POC) °Ë»ç ÀåºñÀÇ °³¹ß·Î ¿ø°ÝÁö³ª ÀÚ¿øÀÌ ºÎÁ·ÇÑ Áö¿ªÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ È¯°æ¿¡¼­ ½Å¼ÓÇÑ °Ë»ç°¡ °¡´ÉÇØÁ® Áß¿äÇÑ Áø´Ü¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ °³¼±µÇ¸é¼­ Ç÷¾× °Ë»ç´Â Å©°Ô º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº Ç÷¾×°Ë»çÀÇ ÇѰ踦 ¶Ù¾î³Ñ¾î Á¶±â ¹ß°ß, º¸´Ù ¸ÂÃãÈ­µÈ Ä¡·á ¿É¼Ç, ȯÀÚ ¿¹ÈÄ °³¼±ÀÇ °¡´É¼ºÀ» Á¦°øÇÕ´Ï´Ù.

Ç÷¾× °Ë»ç ½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

Ç÷¾× °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀº ÀÇ·á ºÐ¾ß¿¡¼­ ¾ÈÀüÇϰí Á¤È®ÇÑ Áø´ÜÀÇ Á߿伺ÀÌ °­Á¶µÇ´Â ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â ƯÈ÷ ÀÇ·á ÀÎÇÁ¶ó°¡ È®´ëµÇ°í ÀÖ´Â ½ÅÈï ½ÃÀå¿¡¼­ Ç÷¾× ¹× Ç÷¾× Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¼ö¼ú, ¼öÇ÷ ¹× À̽ÄÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °¨¿°¼º ÁúȯÀÇ ÀüÆÄ¸¦ ¹æÁöÇϱâ À§ÇÑ ¾ö°ÝÇÑ Ç÷¾× °Ë»çÀÇ Çʿ伺ÀÌ ´õ¿í Àý½ÇÇØÁö°í ÀÖ½À´Ï´Ù. ÇÙ»ê °Ë»ç(NAT)¿Í Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS)°ú °°Àº ±â¼ú ¹ßÀüÀº º¸´Ù Á¤È®Çϰí È¿À²ÀûÀÎ ½ºÅ©¸®´× ¿É¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í Á¶±â ¹ß°ß ¹× ¿¹¹æ ÀÇÇп¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ Á¾ÇÕÀûÀÎ Ç÷¾× ¼±º° °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê¿Í ±ÔÁ¦¿¡ ÀÇÇØ µÞ¹ÞħµÇ´Â °øÁߺ¸°Ç ±âÁØ °³¼±¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ ³ë·ÂÀº Ç÷¾× °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº Áø´Ü ±â¼úÀÇ Áö¼ÓÀûÀÎ Çõ½Å°ú ÇÔ²² Çö´ë ÀÇ·á¿¡¼­ Ç÷¾× °Ë»çÀÇ Áß¿äÇÑ ¿ªÇÒÀ» °­Á¶Çϰí Àü ¼¼°è ȯÀÚÀÇ ¾ÈÀü°ú º¹Áö¸¦ º¸ÀåÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(ÃÑ 12°³»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Blood Screening Market to Reach US$3.8 Billion by 2030

The global market for Blood Screening estimated at US$2.6 Billion in the year 2023, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2023-2030. Nucleic Acid Test (NAT), one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Enzyme-Linked Immunosorbent Assay (ELISA) segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$697.7 Million While China is Forecast to Grow at 9.1% CAGR

The Blood Screening market in the U.S. is estimated at US$697.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$831.4 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Blood Screening Market - Key Trends and Drivers Summarized

Why Is Blood Screening Essential in Ensuring Safe Healthcare Practices?

Blood screening is a critical process in healthcare, designed to detect infectious agents, genetic disorders, and other health conditions in blood samples before they are used for transfusions, organ transplants, or diagnostic purposes. This screening process is vital to ensuring that blood and blood products are safe for use, thereby preventing the transmission of diseases such as HIV, hepatitis, and syphilis. Blood screening also plays a crucial role in the early detection of conditions like cancer and inherited genetic disorders, allowing for timely intervention and treatment. The accuracy and reliability of blood screening tests are paramount, as they directly impact patient safety and public health. As the demand for safe blood products continues to rise globally, blood screening has become an indispensable component of modern healthcare, protecting patients and ensuring the efficacy of medical treatments.

How Has the Evolution of Technology Transformed Blood Screening Processes?

The field of blood screening has been revolutionized by advancements in technology, leading to faster, more accurate, and comprehensive testing methods. Traditionally, blood screening relied on manual techniques and basic serological tests, which, while effective, were limited in scope and could take days to yield results. The introduction of automated testing systems and molecular diagnostics has drastically improved the speed and accuracy of blood screening. Techniques such as nucleic acid testing (NAT) allow for the detection of viral and bacterial pathogens at a much earlier stage, reducing the risk of transmitting infections through blood transfusions. Additionally, the development of high-throughput screening systems has enabled the processing of large volumes of blood samples more efficiently, which is crucial in meeting the demands of modern healthcare facilities. As a result, the evolution of blood screening technology has not only enhanced the safety of blood products but has also expanded the range of detectable conditions, making it a cornerstone of preventive healthcare.

What Are the Emerging Trends and Innovations in Blood Screening Technology?

Blood screening is currently undergoing significant innovation, driven by the need for more comprehensive, faster, and cost-effective diagnostic solutions. One of the most notable trends is the growing use of next-generation sequencing (NGS) in blood screening, which allows for the detailed analysis of genetic material and the identification of a wide range of pathogens and genetic disorders from a single blood sample. Another emerging trend is the integration of artificial intelligence (AI) and machine learning into blood screening processes, which enhances the accuracy of diagnostics by identifying patterns and anomalies that might be missed by conventional methods. Furthermore, the development of point-of-care (POC) testing devices is transforming blood screening by enabling rapid testing in various settings, including remote and resource-limited areas, thus improving access to critical diagnostics. These innovations are pushing the boundaries of what is possible in blood screening, offering the potential for earlier detection, more personalized treatment options, and improved patient outcomes.

What Are the Factors Fueling Expansion of the Blood Screening Market?

The growth in the blood screening market is driven by several critical factors that underscore the increasing importance of safe and accurate diagnostics in healthcare. One of the primary drivers is the rising demand for blood and blood products, particularly in emerging markets where healthcare infrastructure is expanding. As more surgeries, transfusions, and transplants are performed, the need for rigorous blood screening to prevent the transmission of infectious diseases is becoming more urgent. Technological advancements, such as the adoption of nucleic acid testing (NAT) and next-generation sequencing (NGS), are also fueling market growth by offering more precise and efficient screening options. Additionally, the increasing prevalence of chronic diseases and the growing focus on early detection and preventive care are boosting the demand for comprehensive blood screening tests. The global push for improved public health standards, supported by government initiatives and regulations, is further driving the expansion of the blood screening market. These factors, combined with ongoing innovations in diagnostic technology, highlight the critical role of blood screening in modern healthcare, ensuring the safety and well-being of patients worldwide.

Select Competitors (Total 12 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â